Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2010. The report serves as a notification to the market regarding the Company's total voting rights and capital structure as of June 30, 2010, in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of June 30, 2010): 5,666,812,236 Ordinary shares of 25p each.
- Treasury Shares: 474,194,158 Ordinary shares.
- Total Voting Rights: 5,192,618,078.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period. The document is a static notification of current capital structure rather than a comparative financial performance report.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors to Verify
- Verify the total number of voting rights (5,192,618,078) to determine notification thresholds under the Financial Services Authority's Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (474,194,158) when calculating the denominator for ownership interest calculations.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or interim financial reports for revenue and profit metrics.